Synonyms
Anticancer drugs; Brivanib; Epidermal growth factor receptor (EGFR) inhibitors; Erlotinib (Tarceva); Fibroblast growth factor receptor (FGFR) inhibitors; Gefitinib (Iressa); Imatinib (Gleevec); Lapatinib (Tyverb); Platelet-derived growth factor receptor (PDGFR) inhibitors; Semaxanib (SU5416); Sorafenib (Nexavar); Sunitinib (Sutent); Vascular endothelial growth factor receptor (VEGFR) inhibitors
Definition
Receptor tyrosine kinase inhibitors (RTKIs) are a class of low molecular weight, membrane-permeable, ATP-competitive compounds that inhibit the enzymatic activity and function of receptor tyrosine kinases.
Receptor tyrosine kinases (RTKs) are a family of a family of 58 membrane-bound cell surface receptors which bind peptide growth factors and cytokines via their extracellular domain leading to receptor autophosphorylation, dimerization and signal transduction leading to altered cell and animal responses.
RTKs play a pivotal role in the development and progression of...
This is a preview of subscription content, log in via an institution to check access.
References
Chou T, Finn RS (2012) Brivanib: a review of development. Future Oncol 8:1083–1090
Kumar SB, Narasu L, Gundla R, Dayam R, J A. R. P. S (2013) Fibroblast growth factor receptor inhibitors. Curr Pharm Des 19:687–701
Latham AM, Bruns AF, Kankanala J, Johnson AP, Fishwick CW, Homer-Vanniasinkam S, Ponnambalam S (2012) Indolinones and anilinophthalazines differentially target VEGF-A- and basic fibroblast growth factor-mediated responses in primary human endothelial cells. Br J Pharmacol 165:245–259
Lindauer M, Hochhaus A (2014) Dasatinib. Recent Results Cancer Res 201:27–65
Majem M, Pallares C (2013) An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. Clin Transl Oncol 15:343–357
Negrier S, Raymond E (2012) Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 30:1791–1801
Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I (2009) Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 9:66–76
Roskoski R Jr (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34–74
Smith GA, Fearnley GW, Wheatcroft SB, Tomlinson DC, Harrison MA, Ponnambalam S (2015) The cellular response to vascular endothelial growth factors requires coordinated signal transduction, membrane trafficking and proteolysis. Biosci Rep 35:e00253
Umezawa K (1995) Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Adv Enzyme Regul 35:43–53
Vasudev NS, Reynolds AR (2014) Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17:471–494
Zhong H, Bowen JP (2011) Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways. Curr Top Med Chem 11:1571–1590
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Crown Copyright
About this entry
Cite this entry
Latham, A.M., Kankanala, J., Ponnambalam, S. (2015). Receptor Tyrosine Kinase Inhibitors. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_7196-1
Download citation
DOI: https://doi.org/10.1007/978-3-642-27841-9_7196-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27841-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences